0000000000942669

AUTHOR

Justine Paris

showing 1 related works from this author

Impact of granulocyte colony‐stimulating factor on FOLFIRINOX‐induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach

2020

Aims Granulocyte colony-stimulating factor (G-CSF) is frequently prescribed to prevent chemotherapy-induced neutropenia, but the administration schedule remains empirical in case of bimonthly chemotherapy such as FOLFIRINOX regimen. This pharmacokinetic/pharmacodynamic (PK/PD) study was performed to determine the effect of different G-CSF regimens on the incidence and duration of neutropenia following FOLFIRINOX administration in order to propose an optimal G-CSF dosing schedule. Methods A population PK/PD model was developed to describe individual neutrophil time course from absolute neutrophil counts (ANC) obtained in 40 advanced cancer patients receiving FOLFIRINOX regimen. The structura…

OncologyAdultMalemedicine.medical_specialtyNeutropeniaFOLFIRINOXPopulationLeucovorinNeutropeniaIrinotecan030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansPharmacology (medical)030212 general & internal medicineDosingeducationAgedPharmacologyAged 80 and overeducation.field_of_studybusiness.industryOriginal ArticlesMiddle Agedmedicine.diseaseRecombinant ProteinsGranulocyte colony-stimulating factorOxaliplatinPancreatic NeoplasmsPharmacodynamicsFemaleFolfirinox RegimenFluorouracilbusinessPegfilgrastimmedicine.drug
researchProduct